Exhibit 10.2

 

NEORX CORPORATION

 

--------------------------------------------------------------------------------

 

NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

NEORX CORPORATION

NOTE AND WARRANT PURCHASE AGREEMENT

 

This Note and Warrant Purchase Agreement (the “Agreement”) is made as of the 1st
day of February, 2006 (the “Effective Date”) by and among NeoRx Corporation, a
Washington corporation (the “Company”), and the persons and entities named on
the Schedule of Purchasers attached hereto (individually, a “Purchaser” and
collectively, the “Purchasers”).

 

RECITALS

 

A.            The Purchasers desire to purchase and the Company desires to sell,
subject to shareholder approval and the terms and conditions stated in that
certain Securities Purchase Agreement dated as the date hereof (the “Securities
Purchase Agreement”), up to a maximum of $65,000,000 of Common Stock and
Warrants of the Company.

 

B.            To provide the Company with additional resources to conduct its
business and pursue shareholder approval of the transactions contemplated by the
Securities Purchase Agreement, the Purchasers have agreed, subject to the terms
and conditions of this Agreement, to lend the Company the principal sum of
approximately Three Million Four Hundred Sixty Thousand Dollars ($3,460,000).

 

AGREEMENT

 

Now, Therefore, in consideration of the foregoing, and the representations,
warranties, covenants and conditions set forth below, the Company and each
Purchaser, intending to be legally bound, hereby agree as follows:

 

1.                                      Amount and Terms of the Loan; Issuance
of The Warrants

 

1.1          The Loan.  Subject to the terms of this Agreement, each Purchaser
set forth on the Schedule of Purchasers attached hereto (each, a “Purchaser”)
agrees to lend to the Company at the Loan Closing (as defined in Section 4.3),
the amount set forth opposite each such Purchaser’s name under the column
entitled “Loan Amount” on the Schedule of Purchasers attached hereto (each, a
“Loan Amount” and collectively, the “Total Loan Amount” or “Loan”) against the
issuance and delivery by the Company of a convertible promissory note or notes
for such amount(s), in substantially the form attached hereto as Exhibit A
(each, a “Note” and collectively, the “Notes”).  Each Note may be converted into
shares of the Company’s Common Stock as provided in such Note.

 

1.2          Issuance of Warrants.  On the Loan Closing Date (as defined in
Section 4.3), the Company shall, as additional consideration for the Loan, issue
to each Purchaser a warrant in substantially the form attached hereto as Exhibit
B (each, a “Bridge Warrant” and collectively the “Bridge Warrants”).

 

1

--------------------------------------------------------------------------------

 

1.3          Definitions.  Capitalized terms not otherwise defined herein shall
have the respective meanings ascribed thereto in the Securities Purchase
Agreement.

 

2.                                      Representations and Warranties of the
Company

 

2.1          Representations and Warranties of the Company.  The Company hereby
covenants and agrees that all representations and warranties of the Company set
forth in Article 2 of the Securities Purchase Agreement are true and correct as
of the Loan Closing Date, which representations and warranties are incorporated
herein by this reference with the same force and effect as though each such
representation and warranty was set forth in full herein.

 

3.                                      Representations and Warranties of the
Purchasers

 

3.1          Representations and Warranties of the Purchasers.  Each Purchaser
hereby covenants and agrees that all representations and warranties of the
Purchasers set forth in Article 3 of the Securities Purchase Agreement are true
and correct as of the Loan Closing Date, which representations and warranties
are incorporated herein by this reference with the same force and effect as
though each such representation and warranty was set forth in full herein.

 

4.                                      Conditions to Closing

 

4.1.         Conditions to the Company’s Obligations under this Agreement.  The
Company’s obligation to issue and deliver the Notes and Bridge Warrants to each
Purchaser is subject to the fulfillment or waiver as of the Loan Closing Date of
the following conditions:

 

(a)           Receipt of Proceeds.  The Company shall have received payment of
the Total Loan Amount, paid by the Purchasers pursuant to the allocation as set
forth opposite each Purchaser’s name on Exhibit A hereto.  The Total Loan Amount
shall be paid in immediately available funds, in US dollars.

 

(b)           Representations and Warranties.  The representations and
warranties made by each Purchaser in Article 3 of the Securities Purchase
Agreement and herein shall be true and correct in all material respects when
made and as of the Loan Closing Date.

 

(c)           Covenants.  All covenants, agreements and conditions contained in
this Agreement and the Securities Purchase Agreement to be performed by the
Purchasers on or prior to the Loan Closing Date shall have been performed or
complied with in all material respects.

 

(d)           Blue Sky.  The Company shall have obtained all necessary blue sky
law permits and qualifications, or secured exemptions therefrom, required by any
state or foreign or other jurisdiction for the issuance of the Notes, the Bridge
Warrants and the Issuable Common Stock (defined below).

 

(e)           Nasdaq Qualification.  The shares of the Company’s Common Stock
issuable upon conversion of the Note and upon exercise of the Bridge Warrants
(the “Issuable Common Stock”) shall be duly authorized for listing by Nasdaq,
subject to official notice of issuance, to the extent required by the rules of
Nasdaq.

 

2

--------------------------------------------------------------------------------

 

(f)            Absence of Litigation.  No proceeding challenging this Agreement
or the Securities Purchase Agreement and the other Related Agreements or the
transactions contemplated hereby or thereby, or seeking to prohibit, alter,
prevent or materially delay the Loan Closing, shall have been instituted or be
pending before any court, arbitrator, governmental body, agency or official.

 

(g)           No Governmental Prohibition or Third Party Consents.  The issuance
of the Notes, the Bridge Warrants and the Issuable Common Stock by the Company
shall not be prohibited by any law or governmental order or regulation and any
governmental, regulatory or third party consents of approvals, if any, necessary
for the sale of the Notes, the Bridge Warrants and the Issuable Shares shall
have been obtained.

 

4.2.         Conditions to the Purchaser’s Obligations under this Agreement. 
Each Purchaser’s obligation to complete the purchase and sale of the Notes and
Bridge Warrants is subject to the fulfillment or waiver as of the Loan Closing
Date of the following conditions:

 

(a)           Representations and Warranties.  The representations and
warranties made by the Company in Article 2 of the Securities Purchase Agreement
and herein shall be true and correct in all material respects when made and as
of the Loan Closing Date.

 

(b)           Covenants.  All covenants, agreements and conditions contained in
this Agreement and the Securities Purchase Agreement to be performed by the
Company on or prior to the Loan Closing Date shall have been performed or
complied with in all material respects.

 

(c)           Compliance with Laws.  The acquisition of the Notes, the Bridge
Warrants and the Issuable Common Stock by each Purchaser hereunder shall be
legally permitted by all laws and regulations to which each Purchaser or the
Company is subject (including all applicable federal, state and foreign
securities laws).

 

(d)           Legal Opinion.  The Company shall have delivered to such Purchaser
an opinion, dated as of the Loan Closing Date, from Perkins Coie LLP, counsel to
the Company, in substantially the form attached hereto as Exhibit D.

 

(e)           Nasdaq Qualification.  The Issuable Common Stock shall be duly
authorized for listing by Nasdaq, subject to official notice of issuance, to the
extent required by the rules of Nasdaq.

 

(f)            Absence of Litigation.  No proceeding challenging this Agreement
or the Securities Purchase Agreement and the Related Agreements or the
transactions contemplated hereby or thereby, or seeking to prohibit, alter,
prevent or materially delay the Loan Closing, shall have been instituted or be
pending before any court, arbitrator, governmental body, agency or official.

 

(g)           No Governmental Prohibition or Third Party Consents.   The
issuance of the Notes, the Bridge Warrants and the Issuable Common Stock by the
Company shall not be prohibited by any law or governmental order or regulation
and any governmental, regulatory or third party consents of approvals, if any,
necessary for the sale of the Notes, the Bridge Warrants and the Issuable Common
Stock shall have been obtained.

 

3

--------------------------------------------------------------------------------

 

(h)           No Material Adverse Effect. There shall not have occurred a
Material Adverse Effect.

 

(i)            Execution and Delivery of Documents.  The following documents, in
a form satisfactory to Purchasers, shall have been duly executed, acknowledged
and delivered by all parties thereto, and shall be in full force and effect:

 

(i)            The Securities Purchase Agreement;

 

(ii)           This Agreement;

 

(iii)         The Notes;

 

(iv)          The Bridge Warrants;

 

(v)            A certificate from an officer of the Company with respect to
incumbency and resolutions authorizing the execution and delivery of this
Agreement and the Related Agreements;

 

(vi)          A Security Agreement of even date herewith the form of which is
attached hereto as Exhibit C (the “Security Agreement” and collectively with the
Securities Purchase Agreement and this Agreement, the “Operative Agreements”);

 

(vii)         A UCC National Form financing statement covering all of the
Collateral described in the Security Agreement shall have been recorded or filed
for record in each public office wherein such recording or filing is deemed
necessary or appropriate by the Purchasers to perfect the lien thereof as
against creditors of or purchasers from the Company.  Without limiting the
foregoing, all taxes, fees and other charges in connection with the execution,
delivery, recording and filing of the foregoing instruments shall have been paid
or allowance therefor shall have been made;

 

(viii)        Such documents and evidence to establish the existence and good
standing of the Company and the authorization of the transactions contemplated
by the Operative Agreements; and

 

(ix)          Such other documents or certificates and completion of such other
matters, as the Purchasers may reasonably deem necessary or appropriate.

 

(j)            The Company and Texas State Bank shall have entered into a
Forbearance Agreement in the form acceptable to the Purchasers.

 

(k)           The Company and each holder of Series B Convertible Preferred
Stock shall have entered into the Irrevocable Agreement to Convert Series B
Convertible Preferred Stock in the form attached hereto as Exhibit E.

 

4.3          Closing Date.  The closing of the Loan (the “Loan Closing”) shall
be held on the date upon which all of the conditions set forth in Sections 4.1
and 4.2 have been satisfied or waived by the party in whose favor such condition
runs (the “Loan Closing Date”).

 

4

--------------------------------------------------------------------------------

 

4.4          Delivery and Closing Actions.  At the Loan Closing (i) each
Purchaser shall deliver to the Company a check or wire transfer funds in the
principal amount of such Purchaser’s applicable Loan Amount; (ii) the Company
shall issue and deliver to each Purchaser concurrently upon receipt of
Purchaser’s Loan Amount (a) a Note in favor of such Purchaser payable in the
principal amount of such Purchaser’s applicable Loan Amount and (b) a
corresponding Bridge Warrant as specified in Section 1.2.

 

5.                                      Overall Cap on Notes, Bridge Warrants
and Common Shares Issuable to Purchasers.

 

5.1          Notwithstanding anything in this Agreement, the Notes, the Bridge
Warrants or the Operative Agreements to the contrary, if the rules of Nasdaq
require, the Purchaser shall not have the right to acquire the Notes and the
Bridge Warrants, or to convert or exercise any portion thereof into shares of
Common Stock in accordance with their terms (such shares of Common Stock being
referred to herein as “Conversion Shares”), to the extent that either (i) the
aggregate number of Conversion Shares issued and issuable by the Company
pursuant to the Notes and the Bridge Warrants exceeds 19.9% of the number of
shares of Common Stock or the voting power of the Company outstanding on the
original date of issuance of the Notes and the Bridge Warrants (“Date of
Original Issuance”) or (ii) after giving effect to such acquisition, conversion
or exercise, the Purchaser (together with the Purchaser’s affiliates) would
beneficially own in excess of 19.9% of the number of shares of the Common Stock
or the voting power of the Company outstanding immediately after the Loan
Closing (the securities issued and issuable up to and in compliance with the
19.9% thresholds described in clauses (i) and (ii) above being referred to
herein as the “Issuable Maximum”), unless the issuance of securities in excess
of the Issuable Maximum shall first be approved by the Company’s shareholders in
accordance with applicable law and the Bylaws and Articles of Incorporation of
the Company.  If at the time of any potential issuance of the Notes and the
Bridge Warrants, or any conversion or exercise thereof, the Conversion Shares
issued and issuable exceed the Issuable Maximum (and if the Company has not
previously obtained the required shareholder approval), the Company shall issue
to the Purchaser a number of Notes, Bridge Warrants and Conversion Shares not
exceeding the Issuable Maximum, and the remainder of the Notes, Warrants and
Conversion Shares to be issued shall constitute “Excess Securities” pursuant to
Section 5.2 below.

 

5.2          In the event that the Purchaser’s receipt of the Notes, Bridge
Warrants and Conversion Shares is restricted based on the Issuable Maximum, the
Company shall promptly call a shareholder’s meeting for the purpose of obtaining
shareholder approval of the issuance of the Excess Securities to the Purchaser. 
No Conversion Shares issued upon exercise of any Notes or Bridge Warrants
acquired pursuant to this Agreement shall be entitled to vote to approve the
issuance of the Excess Shares.

 

5.3          Neither the Company nor the Purchasers may waive the provisions of
this Section 5.

 

6.                                      Miscellaneous

 

6.1          Binding Agreement.  The terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and
assigns of the parties.  Nothing

 

5

--------------------------------------------------------------------------------

 

in this Agreement, expressed or implied, is intended to confer upon any third
party any rights, remedies, obligations, or liabilities under or by reason of
this Agreement, except as expressly provided in this Agreement.

 

6.2          Governing Law.  This Agreement shall be governed by and construed
under the laws of the State of California, without giving effect to conflicts of
laws principles.

 

6.3          Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

6.4          Titles and Subtitles.  The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

6.5          Notices.  All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the
party to be notified, (b) when sent by confirmed telex, electronic mail or
facsimile if sent during normal business hours of the recipient, if not, then on
the next business day, (c) five (5) days after having been sent by registered or
certified mail, return receipt requested, postage prepaid, or (d) one (1) day
after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt.  All communications shall be
sent to the Company at NeoRx Corporation, 300 Elliott Avenue, West, Suite 500,
Seattle, WA 98119, Attention: Chief Financial Officer, cc: Vice President-
Legal, with copy to Perkins Coie LLP, 1201 Third Avenue, Suite 4800, Seattle, WA
98101, Attention: Faith M. Wilson, and to Purchaser(s) at the address(es) set
forth on the Schedule of Purchasers attached hereto or at such other address(es)
as the Company or Purchase(s)r may designate by ten (10) days advance written
notice to the other parties hereto.

 

6.6          Modification; Waiver.  No modification or permitted waiver of any
provision of this Agreement or consent to departure therefrom shall be effective
unless in writing and approved by the Company and the Purchasers (i) that have
agreed to purchase a 60%  in interest of the aggregate principal amount of the
Notes to be issued, or (ii) if after the Note Closing, that hold at least 60% in
interest of the aggregate principal amount of the then outstanding Notes;
provided, however, that any such modification, waiver or consent that adversely
affects any Purchaser in a different manner than other Purchasers shall require
the consent of such Purchaser.  For purposes of this provision, differences in
investments or ownership among Purchasers shall not be considered as a basis for
determining whether a modification, waiver or consent results in adversely
affecting a Purchaser in a different manner.

 

6.7          Delays or Omissions.  It is agreed that no delay or omission to
exercise any right, power or remedy accruing to each Purchaser, upon any breach
or default of the Company under this Agreement, the Security Agreement or any
Note or Bridge Warrant shall impair any such right, power or remedy, nor shall
it be construed to be a waiver of any such breach or default, or any
acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring.  It
is further agreed that any waiver, permit, consent or approval of any kind or
character by the Purchasers of any breach or default under this Agreement, or
any waiver by any Purchaser of any provisions or conditions of this Agreement

 

6

--------------------------------------------------------------------------------

 

must be in writing and shall be effective only to the extent specifically set
forth in writing and that all remedies, either under this Agreement, or by law
or otherwise afforded to the Purchaser, shall be cumulative and not alternative.

 

6.8          Entire Agreement.  This Agreement, the Exhibits hereto and the
Security Agreement constitute the full and entire understanding and agreement
between the parties with regard to the subjects hereof and no party shall be
liable or bound to any other party in any manner by any representations,
warranties, covenants and agreements except as specifically set forth herein.

 

7

--------------------------------------------------------------------------------

 

In Witness Whereof, the parties have executed this Note and Warrant Purchase
Agreement as of the date first written above.

 

 

 

NeoRx Corporation

 

 

 

 

 

/s/  Gerald Mcmahon

 

 

Gerald McMahon

 

Chairman and Chief Executive Officer

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this NOTE AND WARRANT PURCHASE
AGREEMENT as of the date first written above.

 

 

PURCHASERS:

 

DEERFIELD SPECIAL SITUATIONS FUND,
LTD.

 

 

 

By:

/s/ Darren Levine

 

 

Name:

Darren Levine

 

 

Title:

CFO

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this NOTE AND WARRANT PURCHASE
AGREEMENT as of the date first written above.

 

 

PURCHASERS:

 

DEERFIELD SPECIAL SITUATIONS FUND
INTERNATIONAL, LTD.

 

 

 

By:

/s/ Darren Levine

 

 

Name:

Darren Levine

 

 

Title:

CFO

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

 

 

MPM BIOVENTURES III, L.P.

 

 

 

 

By:     MPM BioVentures III GP, L.P., its
General Partner

 

By:   MPM BioVentures III LLC, its General
Partner

 

 

 

By:

/s/ Nicholas J. Simon

 

 

Name: Nicholas J. Simon

 

Title: Series A Member

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

 

 

 

MPM BIOVENTURES III-QP, L.P.

 

 

 

By:     MPM BioVentures III GP, L.P., its
General Partner

 

By:   MPM BioVentures III LLC, its General
Partner

 

 

 

By:

/s/ Nicholas J. Simon

 

 

Name: Nicholas J. Simon

 

Title: Series A Member

 

 

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

 

 

MPM BIOVENTURES III GMBH & CO.
BETEILIGUNGS KG

 

 

 

 

By:   MPM BioVentures III GP, L.P., in its
capacity as the Managing Limited Partner

 

By:   MPM BioVentures III LLC, its General
Partner

 

 

 

By:

/s/ Nicholas J. Simon

 

 

Name: Nicholas J. Simon

 

Title: Series A Member

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

 

 

 

MPM BIOVENTURES III PARALLEL
FUND, L.P.

 

 

 

By:    MPM BioVentures III GP, L.P., its
General Partner

 

By:   MPM BioVentures III LLC, its General
Partner

 

 

 

By:

/s/ Nicholas J. Simon

 

 

Name: Nicholas J. Simon

 

Title: Series A Member

 

 

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

 

 

MPM ASSET MANAGEMENT INVESTORS
2005 BVIII LLC

 

 

 

By:

/s/ Nicholas J. Simon

 

 

Name: Nicholas J. Simon

 

Title: Manager

 

 

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

 

 

 

MPM BIOEQUITIES MASTER FUND, LP

 

 

 

By:  MPM BioEquities GP, L.P., its General
Partner

 

By:  MPM BioEquities GP LLC, its General
Partner

 

 

 

By:

/s/ Kurt Von Emster

 

 

 

 Manager

 

 

 

 

 

 

 

Address:

The John Hancock Tower

 

 

 

200 Clarendon Street, 54th Floor

 

 

 

Boston, MA 02116

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

 

 

Bay City Capital Management IV, LLC

 

General Partner of:

 

Bay City Capital Fund IV Co-Investment
Fund, L.P.

 

 

 

/s/ Carl S. Goldfisher

 

 

By: Bay City Capital LLC, its Manager

 

By: Carl S. Goldfisher, M.D., a Managing
Director

 

 

 

 

 

Address:

Bay City Capital

 

 

 

750 Battery Street, Suite 400

 

 

 

San Francisco, CA 94111

 

 

 

 

 

 

Bay City Capital Management IV, LLC
General Partner of:

 

Bay City Capital Fund IV, L.P.

 

 

 

/s/ Carl S. Goldfisher

 

 

By: Bay City Capital LLC, its Manager

 

By: Carl S. Goldfisher, M.D., a Managing
Director

 

 

 

 

 

 

Address:

Bay City Capital

 

 

 

750 Battery Street, Suite 400

 

 

 

San Francisco, CA 94111

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

ABINGWORTH BIOVENTURES IV EXECUTIVES
L.P.

 

 

 

 

 

 

 

 

 

 

By:

/s/ James Abell

 

 

 

 

 

Abingworth Management Ltd.

 

 

Name:

James Abell

 

 

 

 

 

 

Title:

Director

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

ABINGWORTH BIOEQUITIES MASTER FUND
LTD.

 

 

 

 

 

 

 

 

By:

/s/ James Abell

 

 

 

 

 

Abingworth Management Ltd.

 

 

Name:

James Abell

 

 

 

 

 

 

Title:

Director

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

ABINGWORTH BIOVENTURES IV L.P.

 

 

 

 

 

 

 

 

By:

/s/ James Abell

 

 

 

 

 

Abingworth Management Ltd.

 

 

Name:

James Abell

 

 

 

 

 

 

Title:

Director

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASERS:

 

 

 

SMITHFIELD FIDUCIARY LLC

 

 

 

 

 

By:

/s/ Adam J. Chill

 

 

 

 

Name: Adam J. Chill

 

 

 

Title: Authorized Signatory

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASERS:

 

 

 

 

 

 

 

 

 

 

By:

/s/ Steven Bloom

 

 

 

 

Name: Steven Bloom

 

 

 

Title: Managing Director, Sagamore Hill Capital
Management, on behalf of Sagamore Hill Hub Fund,
Ltd.

 

 

 

One Manhattanville Road

 

 

 

Purchase, NY 10577

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASERS:

 

 

 

SHEPHERD INVESTMENTS

 

INTERNATIONAL, LTD.

 

 

 

BY: STARK OFFSHORE MANAGEMENT, LLC
ITS INVESTMENT MANAGER

 

 

 

 

 

By:

/s/ Michael A. Roth

 

 

 

 

Name:

Michael A. Roth

 

 

 

 

Title:

Managing Member

 

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

 

PURCHASER

 

 

 

T. ROWE PRICE ASSOCIATES, INC., AS
REGISTERED INVESTMENT ADVISER TO

 

THE PARTICIPATING T. ROWE PRICE
ACCOUNTS IN THE SCHEDULE OF
PURCHASERS

 

 

 

 

 

By:

/s/ Kris H. Jenner

 

 

(signature)

 

 

 

Kris H. Jenner, Vice President

 

 

(print name and title)

 

 

 

100 E. Pratt Stret

 

 

 

Baltimore, MD 21202

 

 

 

 

Attn: Darrell N. Braman

 

 

Vice President and Associate

 

 

Legal Counsel

 

 

100 E. Pratt Street

 

 

Baltimore, MD 21202

 

 

 

 

 

Phone: 410-345-2013

 

 

Facsimile: 410-345-6575

 

 

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT

 

--------------------------------------------------------------------------------

 

SCHEDULES AND EXHIBITS

 

Schedule of Purchasers

 

Exhibit A:  Form of Convertible Promissory Note

 

Exhibit B:  Form of Bridge Warrant

 

Exhibit C:  Form of Security Agreement

 

Exhibit D:  Form of the Opinion of the Company’s counsel

 

Exhibit E:  Irrevocable Agreement to Convert Series B Preferred Stock

 

--------------------------------------------------------------------------------

 

SCHEDULE OF PURCHASERS

 

Name and Address

 

Loan Amount

 

Warrant Shares

 

 

 

 

 

 

 

Abingworth BioEquities Master Fund Ltd.
38 Jermyn Street
London, England SW1Y6DN
Attention: James Abell

 

$

146,384.60

 

104,560

 

 

 

 

 

 

 

Abingworth Bioventures IV Executives LP
38 Jermyn Street
London, England SW1Y6DN
Attention: James Abell

 

$

1,018.43

 

727

 

 

 

 

 

 

 

Abingworth Bioventures IV LP
38 Jermyn Street
London, England SW1Y6DN
Attention: James Abell

 

$

118,750.81

 

84,822

 

 

 

 

 

 

 

Bay City Capital Fund IV Co-Investment Fund, L.P.
750 Battery Street, Suite 400
San Francisco, CA 94111
Attention: Judy Koh

 

$

16,847.54

 

12,034

 

 

 

 

 

 

 

Bay City Capital Fund IV, L.P.
750 Battery Street, Suite 400
San Francisco, CA 94111
Attention: Judy Koh

 

$

781,614.00

 

558,295

 

 

 

 

 

 

 

Deerfield Special Situations Fund International, Ltd.

780 3rd Avenue, 37th Floor
New York, NY 10017
Attention: Darren Levine

 

$

259,500

 

185,357

 

 

 

 

 

 

 

Deerfield Special Situations Fund, LP
780 3rd Avenue, 37th Floor
New York, NY 10017
Attention: Darren Levine

 

$

139,730.77

 

99,807

 

 

--------------------------------------------------------------------------------

 

MPM Asset Management Investors 2005 BVIII LLC
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

19,648.82

 

14,035

 

 

 

 

 

 

 

MPM BioEquities Master Fund, LP
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

159,692.34

 

114,066

 

 

 

 

 

 

 

MPM BioVentures III GmbH & Co.
Beteiligungs KG
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

93,739.39

 

66,956

 

 

 

 

 

 

 

MPM BioVentures III Parallel Fund, L.P.
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

33,508.77

 

23,935

 

 

 

 

 

 

 

MPM BioVentures III, L.P.
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

74,589.61

 

53,278

 

 

 

 

 

 

 

MPM BioVentures III-QP, L.P.
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
Attention: Nicholas Simon

 

$

1,109,282.61

 

792,344

 

 

 

 

 

 

 

Sagamore Hill Hub Fund, Ltd.
One Manhattanville Road
Purchase, NY 10577
Attention: Patrick Sikes

 

$

52,863.73

 

37,760

 

 

--------------------------------------------------------------------------------

 

Shepherd Investments International, Ltd.
3600 South Lake Drive
St. Francis, WI 53235
Attention: Todd Turall

 

$

239,538.46

 

171,099

 

 

 

 

 

 

 

Smithfield Fiduciary LLC
c/o Highbridge Capital Management LLC
9 West 57th Street, 27th Floor
New York, NY 10019
Attention: Ari J. Storch

 

$

79,846.15

 

57,033

 

 

 

 

 

 

 

T. Rowe Price Health Sciences Fund, Inc.
c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

99,115.69

 

70,797

 

 

 

 

 

 

 

T. Rowe Price Health Sciences Portfolio, Inc.
c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

745.23

 

532

 

 

 

 

 

 

 

TD Mutual Funds - TD Health Sciences Fund
c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

7,325.62

 

5,232

 

 

 

 

 

 

 

VALIC Company I – Health Sciences Fund
c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

8,391.33

 

5,994

 

 

 

 

 

 

 

John Hancock Trust – Health Sciences Trust
c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

16,409.20

 

11,721

 

 

 

 

 

 

 

Raytheon Company Combined DB/DC Master Trust - Health Sciences

c/o Darrell N. Braman
100 East Pratt Street
Baltimore, MD 21202

 

$

1,456.93

 

1,040

 

 

 

 

 

 

 

TOTAL

 

$

3,460,000.03

 

2,471,424

 

 

--------------------------------------------------------------------------------

 

Exhibit A

 

Form of Convertible Promissory Note

 

A-1

--------------------------------------------------------------------------------

 

Exhibit B

 

Form of Warrant

 

B-1

--------------------------------------------------------------------------------

 

Exhibit C

 

Form of Security Agreement

 

2

--------------------------------------------------------------------------------

 

Exhibit D

 

Form of Legal Opinion

 

3

--------------------------------------------------------------------------------

 

Exhibit E

 

Irrevocable Agreement to Convert Series B Convertible Preferred Stock

 

4

--------------------------------------------------------------------------------